The current approach to forestalling diabetic complications concentrates on improving blood glucose levels and decreasing HbA1c. Despite “optimal” management with insulin and/or oral hypoglycemic agents and the advent of new anti-diabetic therapies; more than 70% of patients remain out of glycemic control.
RESEARCH & DEVELOPMENT
Glycadia’s experienced R&D team is bringing new scientific discoveries to clinical trials of innovative products for complications of diabetes, including nephropathy, retinopathy and cardiovascular disease.
Meeting a National Health Crisis
With a market exceeding 100 million individuals in the United States alone, Glycadia is out to challenge the epidemic, with results. There are no drugs currently available that directly target diabetes-specific abnormalities underlying the microvascular and macrovascular complications of this disease. Glycadia addresses this massive, yet underserved, critical human healthcare need.
Learn more about Glycadia’s proprietary entities: GLY-230 for diabetic complications; GLY-220 and ES12 mAb for diabetic macrovascular disease; and A717 mAb for diabetic microvascular disease.
Glycadia has completed Phase Ia and Phase Ib/IIa clinical trials with its lead compound, GLY-230, and is preparing for additional Phase II trials of GLY-230 in patients with diabetes at risk for diabetic nephropathy.